key: cord-0750262-9os6ostn
authors: Riou, C.; Schafer, G.; Du Bruyn, E.; Goliath, R.; Stek, C.; Mou, H.; Hung, D.; Wilkinson, K. A.; Wilkinson, R. J.
title: Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells
date: 2020-11-03
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.10.30.20223099
sha: c79e58e97c6787544448f0844bd9c9a75d31b74a
doc_id: 750262
cord_uid: 9os6ostn

Rapid tests to evaluate SARS-CoV-2-specific T cell responses are urgently needed to decipher protective immunity and aid monitoring vaccine-induced immunity. Using a rapid whole blood assay requiring minimal amount of blood, we measured qualitatively and quantitatively SARS-CoV-2-specific CD4 T cell responses in 31 healthcare workers, using flow cytometry. 100% of COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4 T cell response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no COVID-19-associated symptoms or who tested PCR negative. Phenotypic assessment indicated that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early differentiated memory phenotype with limited capacity to produce IFN{gamma}. Conversely, in participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late differentiated cells, co-expressing IFN{gamma} and TNF and also Granzyme B. This proof of concept study presents a scalable alternative to PBMC-based assays to enumerate and phenotype SARS-CoV-2-responding T cells, thus representing a practical tool to monitor adaptive immunity in vaccine trials.

The outbreak of SARS-CoV-2 infection (causing the disease known as COVID-19) that first 51 emerged in Wuhan, China in December 2019, was declared a global pandemic on 12 th March 52 2020, and is affecting all countries of the world, including those of Africa (Margolin et al., 2020) . 53

There is an urgent need to understand better the clinical manifestations and the pathogenesis of 54 SARS-CoV-2 in order to develop relevant tools, including diagnostic tests, treatments and 55 vaccines, to stop the spread of disease as well as strategies to best manage this disease in all 56 population groups. 57

The clinical spectrum of COVID-19 is very wide, from asymptomatic through mild flu-like 59 symptoms to severe pneumonia and death. Understanding what constitutes immune protection 60 against SARS-CoV-2 is key to predicting long-term immunity and to inform vaccine design. 61

While much emphasis has been placed on the B cell and antibody response, it is not yet clear 62 what type of immune response confers protection to SARS-CoV-2 (Cox and Brokstad, 2020) . 63

Several studies suggest that the T cell response may play an important role in SARS-CoV-2 64 pathogenesis and reports indicating that patients lacking B cells can recover from SARS-CoV-2 65 infection further highlight the likely importance of T cell immunity (Altmann and Boyton, 2020) ; 66 (Quinti et al., 2020) . Additionally, accumulating evidence indicates that the presence of pre-67 existing, cross-reactive memory T cells specific for common cold coronaviruses may affect 68 4 (PBMC), requiring significant amount of blood. Therefore, whole blood assays could be more 75 advantageous than PBMC-based methods, by significantly reducing blood volume (~ 1 ml), 76 making them more applicable to paediatric populations. Moreover, such assays are rapid, as they 77 don't require cell separation, and preserve the physiologic cellular and soluble environments, 78 mimicking better human blood condition. Here we report a rapid (~ 7 hrs) whole blood-based 79 detection method of SARS-CoV-2-specific T cell responses with simple steps that could be 80 adapted to settings of limited resources. This rapidly applicable assay could represent an easily 81 standardizable tool to assess SARS-CoV-2-specific adaptive immunity to monitor T cell 82 responses in vaccine trials, gain insight into what constitutes a protective response, or define the 83 prevalence of SARS-CoV-2 T cell responders population wide. 84 7 tuberculosis specific T cells in small volumes of blood (Hanekom et al., 2004) . However, 137 significant modifications have been made, including a reduced incubation time, the usage of a 138 fixation buffer allowing the simultaneous lysis of red blood cells to streamline processing time, 139 leading to faster acquisition of results (Riou et al., 2020) . Here, we adapted this assay to detect 140 SARS-CoV-2 specific T cells using synthetic SARS-CoV-2 PepTivator peptides (Miltenyi 141 Biotec, Surrey, UK), consisting of 15-mer sequences with 11 amino acid overlap covering the 142 immunodominant parts of the spike (S) protein, and the complete sequence of the nucleocapsid 143 (N) and membrane (M) proteins. All peptides were combined in a single pool and used at a final 144 concentration of 1 µg/ml. The workflow of the assay is presented in Figure 1 

Even though RT-PCR is the most specific technique to detect acute SARS-CoV-2 infection, the 175 positivity rate drops rapidly as soon as 10 days post-symptom onset, particularly in individuals 176 with mild forms of COVID-19 (Liu et al., 2020a; Liu et al., 2020b) . Hence, serology assays 177 provide an important complement to RNA testing to identify individuals who have been 178 sensitized by SARS-CoV-2. Thus, to assess potential SARS-CoV-2 sensitization in participants 179 who did not have a SARS-CoV-2 PCR test performed or tested PCR negative, the presence of 180 SARS-CoV-2-specific antibodies (e.g. SARS-CoV-2 nucleocapsid-specific IgG) was measured 181 and a SARS-CoV-2 pseudovirus neutralisation assay was also performed in all participants. 182

While all participants with a positive SARS-CoV-2 PCR test exhibited in vitro anti-SARS-CoV-2 183 neutralizing activity and 8/9 (88.8%) had detectable SARS-CoV-2 nucleocapsid-specific IgG, 184

none of the participants who tested negative or did not undergo PCR testing were positive for 185 SARS-CoV-2 nucleocapsid-specific IgG (Figure 2A ) or displayed robust in vitro anti-SARS-186

CoV-2 activity ( Figure 2B) . Overall, these results confirmed that PCR positive participants had 187 been infected with SARS-CoV-2 and mounted an immune response to the virus and suggested 188 that none of the participants who did not have a PCR test performed or tested PCR negative, 189 despite experiencing COVID-19-like symptoms, have been SARS-CoV-2 infected. 190

Amongst the 31 participants tested, 58% (n=18) had a detectable SARS-CoV-2-specific CD4 T 193 cell response (producing any of the measured cytokines, IFNɣ, TNFα or IL-2) using the described 194 whole blood assay ( Figure 3A) . We then defined the magnitude and phenotype of SARS-CoV-2 195 -specific CD4 responses according to participants' clinical characteristics ( Figure 3B&C ). All 196 HCW with self-reported symptoms and a SARS-CoV-2 PCR positive test (n=9) were found to 197 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. Next, we defined the polyfunctional profile of SARS-CoV-2-responding CD4 T cells, based on 208 their capacity to co-express IL-2, IFNγ or TNFα ( Figure 3D ). The overall functional profile of 209 SARS-CoV-2-specific cells in PCR positive participants was distinct from participants with no 210 reported symptoms (p=0.0002). Indeed, the SARS-CoV-2-specific CD4 response in PCR+ 211 participants was characterized by limited expression of IFNγ and was enriched in cells co-212 expressing IL-2 and TNFα. On the contrary, in participants reporting no symptom, most SARS-213 responding CD4 cells were distributed between triple functional cells (IL-2+IFNγ+TNFα+) and 214 cells co-producing IFNγ and TNFα. Overall, in this assay TNFα was the predominant cytokine 215 produced, with its production being significantly higher compared to IL-2 (p = 0.0026) and IFNγ 216 (p < 0.0001) (Supplementary Figure 2) . 217 218

While the proposed assay can be performed using a limited antibody panel to identify the 220 frequency of SARS-CoV-2-responding T cells, by solely measuring cytokine production, the use 221 of a more extensive antibody panel also permits definition of the phenotypic profile of these cells. 222

To this end, we included additional markers to assess the memory differentiation (CD27, 223 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. ;

12 segregation of participants who reported no symptoms and were negative for SARS-CoV-2 Abs 250 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. out that all these studies were performed using PBMC and it is encouraging to find that a whole 287 blood-based assay using limited amount of blood (< 1ml) yields comparable results. 288 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. ; 14 2020; Sattler et al., 2020). However, it is also possible that the limited IFNγ production, we 294 observed in this study, is related to the short stimulation time (e.g. 5hrs) used in the assay. 295

Nevertheless, this suggests that TNFα could be a more reliable target than IFNγ, to detect SARS- Although our results rely on a small number of participants and need to be confirmed in 317 larger cohorts, this study suggests that a whole blood assay could represent a valuable tool to 318 assess SARS-CoV-2-specific adaptive immunity. The whole blood assay described here is rapid 319 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.30.20223099 doi: medRxiv preprint 15 and scalable for varying complexities depending on laboratory resources and questions to be 320 addressed. It can be adapted to a simple 4-colour flow cytometry assay to monitor the frequency 321 of T cell responses in epidemiological studies or vaccine trials. Alternatively, it can also be used 322 to characterize in more depth the specific attributes of SARS-CoV-2-specific T cells, as shown 323 here, to aid deciphering cellular features that may associate with immune correlates of protection. 324

Finally, as this standardizable assay requires a limited volume of blood, it can be easily used in 325 COVID-19 paediatric cases. 326 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 3, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

SARS-CoV-2 T cell immunity: Specificity, function, 434 durability, and role in protection

Restoring function in exhausted CD8 T cells during chronic viral infection

Albrecht, and 440 B.R. tenOever. 2020. Imbalanced host response to SARS-CoV-2 drives development of 441 COVID-19

SARS-CoV-2-reactive T cells in 447 healthy donors and patients with COVID-19

Generation of HPV pseudovirions 451 using transfection and their use in neutralization assays

COVID-19 makes B cells forget, but T cells remember

2020. T cell responses in patients with COVID-19

Not just antibodies: B cells and T cells mediate immunity to 457 COVID-19

Clinical 459 performance of the Elecsys electrochemiluminescent immunoassay for the detection of 460 SARS-CoV-2 total antibodies

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-465 19 disease and unexposed individuals

Novel application of a whole blood 469 intracellular cytokine detection assay to quantitate specific T-cell frequency in field 470 studies

The role of PD-1 in 472 acute and chronic infection

Cytotoxic CD4 T cells -Friend or foe during viral infection? Front Immunol

SARS-CoV-2-specific T cell 478 immunity in cases of COVID-19 and SARS, and uninfected controls

Cross-reactive memory T cells and herd 481 immunity to SARS-CoV-2

A preliminary study on serological 485 assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 486 admitted hospital patients

Viral dynamics in mild and severe cases of COVID-19

Prospects for SARS-CoV-2 diagnostics, therapeutics 492 and vaccines in Africa

Deep 499 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic 500 implications

Clinical 506 management of COVID-19: Experiences of the COVID-19 epidemic from Groote Schuur 507 Hospital

2020. 510 Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-511

Development and 514 validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for 515 determining past exposure to SARS-CoV-2

CoV-2: a head-to-head benchmark comparison

2020. T cell assays 521 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral 522 responses

524 Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-525 specific CD4+ T cells targeted to vascular endothelium

A possible role for B cells in COVID-19? Lesson from patients 529 with agammaglobulinemia

Disease extent and anti-tubercular treatment 532 23 response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype 533 regardless of HIV-1 status

Isolation of potent SARS-CoV-2 neutralizing 539 antibodies and protection from disease in a small animal model

Antigen-specific adaptive immunity to SARS-544

CoV-2 in acute COVID-19 and associations with age and disease severity

SARS-CoV-2 specific T-cell responses and correlations 548 with COVID-19 patient predisposition

High levels of SARS-551

CoV-2-specific T cells with restricted functionality in severe courses of COVID-19

Robust T cell immunity in convalescent individuals with asymptomatic or mild 559 COVID-19

PD-1 expression 561 and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible 562 functional anergy

Pre-existing immunity to SARS-CoV-2: the knowns and 564 unknowns

Molecular and cellular insights into T cell exhaustion

Immune checkpoint blockade in infectious diseases

Elevated exhaustion levels and reduced functional diversity of T cells in 571 peripheral blood may predict severe progression in COVID-19 patients

The authors thank all the participants. 327